KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China.

Jianchun Yu, Wei Chen, Gang Xiao, Qi An, Ziyu Li, Bin Liang, Yuanxin Li, Dongbing Zhao, Junsheng Peng, Yanbing Zhou, Guole Lin, Weiming Kang, Zijian Li, Chao Yan, Yuanpei Lin, Changzhen Zhu, Hu Ren, Yijia Lin, Yulong Tian

Asia Pac J Clin Nutr 35(3) 463-474

PMID42242853
PMCIDPMC13236445
DOI10.6133/apjcn.202606_35(3).0009
发表日期2026-06-04
入排依据:The study is a randomized Phase III trial in oncology patients with a primary efficacy endpoint, but the endpoint is a change in a nutritional biomarker (pre-albumin), not a time-to-event outcome like OS or PFS. The intervention is a nutritional formula, not a drug, and there is no Kaplan-Meier analysis or hazard ratio. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND AND OBJECTIVES: This study aimed to evaluate the safety and efficacy of a fish oil-enriched food for special medical purposes (FSMP, ProSure) compared to an oncology-specific enteral nutrition product (TPF-T). METHODS AND STUDY DESIGN: This multicenter, randomized, open-label, non-inferiority phase III trial (NCT05301556) included patients with gastrointestinal tumors scheduled for surgery and at high risk for malnutrition. Participants were randomized 1:1 to receive either FSMP or TPF-T as a sole nutritional source from 4±2 days before surgery to 9±3 days postoperatively. The primary endpoint was the change in serum pre-albumin levels from baseline to 9±3 days post-surgery (non-inferiority margin: 20.807 mg/L). RESULTS: Of the 325 patients randomized (FSMP: n = 162; TPF-T: n = 163), FSMP demonstrated non-inferiority to TPF-T in maintaining serum pre-albumin levels in the perioperative patients (least square [LS] mean differ-ence: 6.9 mg/L, 95% CI: -5.0 to 18.8). FSMP showed a greater reduction in serum triglycerides (LS mean difference: -0.133 mmol/L, 95% CI: -0.239 to -0.027, p = 0.014), while comparable changes in other lipid parameters, serum albumin, body weight, or grip strength from baseline to 9±3 days post-surgery, and the length of hospital stay were observed between groups (all p >0.05). The most common treatment-emergent adverse events were gastrointestinal disorders, including abdominal distension (FSMP: 17.3% vs. TPF-T: 18.4%), di-arrhea (21.0% vs. 11.0%), and nausea (6.8% vs. 5.5%). CONCLUSIONS: ProSure, an FSMP, when used as a sole nutritional source, is not inferior to TPF-T in maintaining perioperative nutritional status in patients with gastrointestinal tumors, demonstrating comparable efficacy and safety.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。